PAIA Biotech GmbH offers assays for
the rapid quantification of antibodies
and proteins based on its proprietary
PAIA Biotech has developed a patented detection technology using special microplates for high throughput assays in small volumes.
Two product lines have been launched for the platform, titer and glycan screening kits and others are under development. We appreciate the support of our large network of customers and partners in developing these exciting novel assay solutions.
In addition to off-the-shelf assay products PAIA Biotech GmbH offers the first glycan screening assay service that can cope with the sample numbers and turnaround requirements of cell culture labs.
PAIA Biotech GmbH is based in the center of Europe, Cologne/Germany.
We are proud to be a partner in this international
research consortium, a project funded by the Innovatice Medicines Initaitive (IMI). It aims at developing an integrated control and sensing platform for biopharmaceutical cultivation processes.
The consortium consists of 19 partners from the biopharmaceutical industry, small and medium
technology provides and universities.
Further information can be found on the IMI website.
The “Targeted Improvement of Therapeutic Protein Quality Through Cell Culture Media” (TIPQMed) project seeks to identify cell culture media compositions that allow precise modulation of product quality attributes using high throughout technologies to systematically
test a multitude of conditions.
The consortium is led by Florabio (Turkey) and comprises technology providers PAIA Biotech (Germany), GlycoMScan (Netherlands) and Biberach University of Applied Sciences (Germany).
GET IN TOUCH WITH US